Merck & Co closes higher on Keytruda promise in adjuvant lung cancer study

18 March 2022
merck_co_large

US pharma giant Merck & Co (NYSE: MRK) closed 1% higher on Thursday.

The company had earlier announced results from a Phase III trial alongside the European Organization for Research and Treatment of Cancer and the European Thoracic Oncology Platform.

"The sixth positive pivotal study evaluating a Keytruda-based regimen in earlier stages of cancer"It was found that adjuvant treatment with Keytruda (pembrolizumab) significantly improved disease-free survival (DFS), one of the study’s dual primary endpoints, reducing the risk of disease recurrence or death by 24% compared to placebo in stage IB to IIIA non-small cell lung cancer (NSCLC) following surgical resection, regardless of PD-L1 expression.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology